Novel Clinical and Laboratorial Challenges in Aspergillosis

In recent years, research in the areas of <i>Aspergillus</i> and aspergillosis has continued to advance rapidly, including advancements in genomics, immunological studies, clinical areas, and diagnostic areas. Recently, new risk groups for the development of aspergillosis have emerged—pa...

Full description

Bibliographic Details
Main Authors: Raquel Sabino, Cristina Veríssimo
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/10/2/259
_version_ 1797477830826655744
author Raquel Sabino
Cristina Veríssimo
author_facet Raquel Sabino
Cristina Veríssimo
author_sort Raquel Sabino
collection DOAJ
description In recent years, research in the areas of <i>Aspergillus</i> and aspergillosis has continued to advance rapidly, including advancements in genomics, immunological studies, clinical areas, and diagnostic areas. Recently, new risk groups for the development of aspergillosis have emerged—patients with influenza- or COVID-19-ssociated pulmonary aspergillosis. The rise and spread of antifungal resistances have also become a clinical concern in some geographic areas and have drawn the attention of clinicians due to difficulties in treating these infections. In this paper, a snapshot of these issues is presented, emphasizing these novel clinical and laboratorial challenges in the aspergillosis field and focusing on their actual relevance.
first_indexed 2024-03-09T21:23:19Z
format Article
id doaj.art-04704acf7e644b57a2a2d54f19813f3d
institution Directory Open Access Journal
issn 2076-2607
language English
last_indexed 2024-03-09T21:23:19Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Microorganisms
spelling doaj.art-04704acf7e644b57a2a2d54f19813f3d2023-11-23T21:13:19ZengMDPI AGMicroorganisms2076-26072022-01-0110225910.3390/microorganisms10020259Novel Clinical and Laboratorial Challenges in AspergillosisRaquel Sabino0Cristina Veríssimo1Reference Unit for Parasitic and Fungal Infections, Department of Infectious Diseases, National Institute of Health, 1649-016 Lisbon, PortugalReference Unit for Parasitic and Fungal Infections, Department of Infectious Diseases, National Institute of Health, 1649-016 Lisbon, PortugalIn recent years, research in the areas of <i>Aspergillus</i> and aspergillosis has continued to advance rapidly, including advancements in genomics, immunological studies, clinical areas, and diagnostic areas. Recently, new risk groups for the development of aspergillosis have emerged—patients with influenza- or COVID-19-ssociated pulmonary aspergillosis. The rise and spread of antifungal resistances have also become a clinical concern in some geographic areas and have drawn the attention of clinicians due to difficulties in treating these infections. In this paper, a snapshot of these issues is presented, emphasizing these novel clinical and laboratorial challenges in the aspergillosis field and focusing on their actual relevance.https://www.mdpi.com/2076-2607/10/2/259<i>Aspergillus</i>invasive aspergillosisantifungal resistancesCAPAIAPA
spellingShingle Raquel Sabino
Cristina Veríssimo
Novel Clinical and Laboratorial Challenges in Aspergillosis
Microorganisms
<i>Aspergillus</i>
invasive aspergillosis
antifungal resistances
CAPA
IAPA
title Novel Clinical and Laboratorial Challenges in Aspergillosis
title_full Novel Clinical and Laboratorial Challenges in Aspergillosis
title_fullStr Novel Clinical and Laboratorial Challenges in Aspergillosis
title_full_unstemmed Novel Clinical and Laboratorial Challenges in Aspergillosis
title_short Novel Clinical and Laboratorial Challenges in Aspergillosis
title_sort novel clinical and laboratorial challenges in aspergillosis
topic <i>Aspergillus</i>
invasive aspergillosis
antifungal resistances
CAPA
IAPA
url https://www.mdpi.com/2076-2607/10/2/259
work_keys_str_mv AT raquelsabino novelclinicalandlaboratorialchallengesinaspergillosis
AT cristinaverissimo novelclinicalandlaboratorialchallengesinaspergillosis